{"id":"dha-ppq-group","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dihydroartemisinin (DHA), a semi-synthetic artemisinin derivative, acts rapidly against malaria parasites by generating free radicals that damage parasite proteins and organelles. Piperaquine is a bisquinoline that accumulates in the parasite's food vacuole and inhibits hemoglobin digestion and heme detoxification. The combination provides rapid parasite clearance (DHA) with extended post-treatment prophylaxis (piperaquine's long half-life).","oneSentence":"DHA-PPQ is a fixed-dose combination of dihydroartemisinin and piperaquine that kills malaria parasites by generating reactive oxygen species and disrupting parasite hemoglobin digestion.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:31:52.931Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Uncomplicated malaria caused by Plasmodium falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi"}]},"trialDetails":[{"nctId":"NCT07403643","phase":"PHASE4","title":"Investigating the Pharmacology of Tafenoquine in Papua New Guinean Children With Uncomplicated Malaria","status":"NOT_YET_RECRUITING","sponsor":"Curtin University","startDate":"2026-04","conditions":"Uncomplicated Malaria","enrollment":60},{"nctId":"NCT04778813","phase":"PHASE4","title":"Evaluation of Three Artemisinin-based Combinations for the Treatment of Uncomplicated Malaria in Childreen in Burkina Faso (CHIMIO2)","status":"UNKNOWN","sponsor":"Centre national de recherche et de formation sur le paludisme","startDate":"2021-06-01","conditions":"Malaria, Burkina Faso","enrollment":1050},{"nctId":"NCT02604966","phase":"PHASE4","title":"P. Falciparum Resistance to Artemisinin in Vietnam","status":"UNKNOWN","sponsor":"National Institute of Malariology, Parasitology and Entomology, Vietnam","startDate":"2015-04","conditions":"Drug Resistant Malaria Due to Plasmodium Falciparum","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"DHA - PPQ group","genericName":"DHA - PPQ group","companyName":"National Institute of Malariology, Parasitology and Entomology, Vietnam","companyId":"national-institute-of-malariology-parasitology-and-entomology-vietnam","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DHA-PPQ is a fixed-dose combination of dihydroartemisinin and piperaquine that kills malaria parasites by generating reactive oxygen species and disrupting parasite hemoglobin digestion. Used for Uncomplicated malaria caused by Plasmodium falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}